Phlebia subochracea

Phlebia subochracea
Scientific classification
Domain:	Eukaryota
Kingdom:	Fungi
Division:	Basidiomycota
Class:	Agaricomycetes
Order:	Polyporales
Family:	Meruliaceae
Genus:	Phlebia
Species:	P. subochracea
Binomial name
	Phlebia subochracea; (Alb. & Schwein.) J.Erikss. & Ryvarden (1976)
Synonyms
	Acia membranacea subsp. subochracea(Alb. & Schwein.) Bourdot & Galzin (1914); Acia subochracea(Alb. & Schwein.) Bourdot & Galzin (1928); Grandinia subochracea(Alb. & Schwein.) Bres. (1894); Lilaceophlebia subochracea(Alb. & Schwein.) Spirin & Zmitr. (2004); Mycoacia subochracea(Alb. & Schwein.) Parmasto (1967); Peniophora danicaM.P.Christ. (1956); Phlebia danica(M.P.Christ.) M.P.Christ. (1960); Sarcodontia subochracea(Alb. & Schwein.) Nikol. (1961); Thelephora granulosa var. subochraceaAlb. & Schwein. (1805);

Last updated May 23, 2024

Phlebia subochracea is a fungal plant pathogen.^[1]

Related Research Articles

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.

Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful, is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.

Minhai COVID-19 vaccine, trademarked as KCONVAC, is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.

Turkovac is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.

COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">Noora (vaccine)</span> Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran.

202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech. It is one of several candidates under development by Walvax.

ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.

Stemirna COVID-19 vaccine is a COVID-19 vaccine candidate developed by Stemirna Therapeutics.

INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.

References

↑ Romanelli, Anna M.; Sutton, Deanna A.; Thompson, Elizabeth H.; Rinaldi, Michael G.; Wickes, Brian L. (March 2010). "Sequence-Based Identification of Filamentous Basidiomycetous Fungi from Clinical Specimens: a Cautionary Note". Journal of Clinical Microbiology. 48 (3): 741–752. doi:10.1128/JCM.01948-09. PMC 2832452 . PMID 20042628.

This Polyporales-related article is a stub. You can help Wikipedia by expanding it.

This fungal plant disease article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Romanelli, Anna M.; Sutton, Deanna A.; Thompson, Elizabeth H.; Rinaldi, Michael G.; Wickes, Brian L. (March 2010). "Sequence-Based Identification of Filamentous Basidiomycetous Fungi from Clinical Specimens: a Cautionary Note". Journal of Clinical Microbiology. 48 (3): 741–752. doi:10.1128/JCM.01948-09. PMC 2832452 . PMID 20042628.

[1]